文章
醫療新知 > 新療法 : 結合Tyverb及標靶藥Herceptin兩款藥物治療Her2乳癌

新療法 : 結合Tyverb及標靶藥Herceptin兩款藥物治療Her2乳癌

11-03-2016

 

Drug combination shrinks HER2 positive breast

 

cancers within 11 days

 

A drug combination – of lapatinib and trastuzumab (Herceptin) – before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days. The results are from a Cancer Research UK-funded trial* being presented at the 10th European Breast Cancer Conference (EBCC10)(link is external) today.

The research may lead to fewer women needing chemotherapy.

“These results are very promising if they stand up in the long run and could be the starting step of finding a new way to treat HER2 positive breast cancers." – Professor Arnie Purushotham, senior clinical adviser at Cancer Research UK

The EPHOS B trial, led by researchers at The Institute of Cancer Research, London, the University of Manchester and University Hospital of South Manchester NHS Foundation Trust, studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.

In the trial, women were split into three groups and treated for 11 days before their surgery. Initially women were randomised to receive either trastuzamab, or lapatinib or no treatment – but halfway through the trial after evidence from other trials of the effectiveness of the combination the design was altered so that additional women allocated to the lapatinib group were also prescribed trastuzumab.

The trial set out to study the biological effects of the drug combination by measuring biological markers of cellular proliferation after 11 days of therapy. But when trying to measure this, the researchers discovered that in roughly a quarter of the 66 women who received both drugs the remaining tumour was too small for the second measurement of cell proliferation.

17 per cent of the women receiving both drugs had only minimal residual disease – defined as an invasive tumour smaller than 5mm in size – and 11 per cent had a pathological complete response – meaning no biological sign of invasive tumour could be found in the breast.

Three per cent of the women treated with trastuzumab only had residual disease or complete response.

HER2 positive breast cancer is more likely to come back after treatment than some other types of breast cancer. It is generally treated with surgery, chemotherapy, endocrine therapy and targeted anti-HER2 drugs.

Around 53,400 women are diagnosed with invasive breast cancer – with about 10-15 per cent of these characterised as HER2 positive breast cancer – and around 11,600 women die  from the disease in the UK every year.

Current treatments are effective, and complete response is common after three to four months, but the researchers say observing a disease response after 11 days was very surprising.

Trial co-leader Professor Judith Bliss, director of the Cancer Research UK-funded clinical trials and statistics unit at The Institute of Cancer Research, London, said: “Our trial set out to try to use the window between diagnosis and surgery to find clues that combined treatment with trastuzumab and lapatinib was having a biological effect on HER2 positive tumours. So it was unexpected to see quite such dramatic responses to the trastuzumab and lapatinib within 11 days.

“Our results are a strong foundation on which to build further trials of combination anti-HER2 therapies prior to surgery – which could reduce the number of women who require subsequent chemotherapy, which is also very effective but can lead to long-term side effects.”

Clinical chief investigator and trial co-leader Professor Nigel Bundred, professor of surgical oncology at The University of Manchester and clinical consultant at University Hospital of South Manchester NHS Foundation Trust, said: “These early and significant tumour regressions seen on dual anti-HER2 therapy suggest that we will be able to personalise treatment for these cancers on the basis of early response, allowing us to identify patients who in the future may avoid treatment morbidity or avoid chemotherapy”.

Professor Arnie Purushotham, senior clinical adviser at Cancer Research UK, said: “These results are very promising if they stand up in the long run and could be the starting step of finding a new way to treat HER2 positive breast cancers. This could mean some women can avoid chemotherapy after their surgery – sparing them the side-effects and giving them a better quality of life.”

Cancer Research UK scientists helped establish the link between some cancers and ‘growth factor receptor’ proteins on the surface of cells – a crucial early step in the development ofHerceptin. Cancer Research UK also funded the clinical trials unit where the research showing that Herceptin can improve survival for people with a certain type of breast cancer was completed.


www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-03-10-drug-combination-shrinks-her2-positive-breast-cancers-within-11-days

———————————————————

 

【治乳癌突破】結合兩種藥醫治 腫瘤最快11日消失


英國發現一種新的乳癌療法,在病人確診後立即給予兩種現有的藥物治療,最快可以在11天之內令腫瘤消失,有醫生甚至形容,未曾見過乳癌病人這麼快就對療程產生反應。

 

新療法由曼徹斯特大學和倫敦的癌症研究學院(Institute of Cancer Research)發現,研究團隊結合泰康達(Tyverb)及標靶藥Herceptin兩款乳癌藥物,向新確診病人立即用藥,原本是希望病人的腫瘤在手術前縮小,後來卻發現有些腫瘤在動手術前已消失。

 

研究在英國23間醫院進行,涉及257名新病人。接受新療法的66名患者中,87%對療法有反應,腫瘤停止產生更多癌細胞,令癌細胞數目下降。11%的患者的腫瘤更已經消失,另外17%病人的腫瘤明顯縮小至直徑少於5毫米。而病人的腫瘤原本直徑達3厘米。

 

帶領研究的曼徹斯特大學癌症外科醫生邦德雷德(Nigel Bundred)非常興奮,稱:「實體腫瘤在11天之內消失是聞所未聞,這些都是令人難以置信的結果。」研究的詳情在阿姆斯特丹的歐洲乳癌會議上公佈。

 

這個療法是針對難纏的HER2型乳癌,雖然患病女性仍需要接受手術確保癌細胞全部消失,但醫生希望這個方法可以令她們免卻化療之苦。

 

英國《每日郵報》/《每日電訊報》


hk.apple.nextmedia.com/realtime/international/20160311/54854039

城中活動

2024-12-16 11:00 上午 花藝班之聖誕篇🎄
2024-12-11 10:30 上午 禪繞白紙磚工作坊
2024-12-11 10:00 上午 好好呼吸郊遊樂(一)

疑難排解

會員註冊


或許你會想看
【大腸癌治療】後線晚期大腸癌系列:聯合治療為患者重燃新曙光 |謝耀昌醫生
大腸癌是本港三大常見癌症之一,2024年發表的最新癌症統計顯示,腸癌新症數目高達5,190宗,死亡個案達2,2 […]
中大醫學院獲李嘉誠基金會捐贈亞洲首台 Histotripsy 2.0 系統 共 30 名患者獲資助接受組織碎化技術治肝癌
香港中文大學(中大)醫學院獲李嘉誠基金會(基金會)捐贈亞洲首台 Histotripsy 2.0 系統,將於明年 […]
港大醫學院統合分析指高危EB病毒譜系與南中國鼻咽癌風險密切相關
香港大學李嘉誠醫學院(港大醫學院)研究團隊發現,特定的EB病毒(Epstein-Barr virus)變異體與 […]
【預防HPV】衞生署十二月二日開展人類乳頭瘤病毒疫苗補種計劃(第一階段)
衞生署十一月六日公布,將於十二月二日開展一次性人類乳頭瘤病毒(HPV)疫苗(又稱子宮頸癌疫苗)補種計劃(第一階 […]
【免費肺癌篩查計劃】癌症資訊網慈善基金啟動新一輪免費肺癌篩查計劃 擴大名額助高風險人士早期發現肺癌 提高治癒機會
癌症資訊網慈善基金啟動新一輪免費肺癌篩查計劃 擴大名額助高風險人士早期發現肺癌 提高治癒機會 【2024年11 […]
【癌症治療】充份理解進行免疫細胞治療所面對的風險
近月有藝人分享前往泰國進行免疫細胞治療 再次引起社群、同路人之間的討論 香港主要是緊隨 FDA 的指引,只有C […]
【脊椎健康】養和發布關於港人脊椎健康調查結果 近九成受訪者受脊椎問題困擾影響日常生活
(2024年10月28日,香港)養和醫療集團(養和)於今年8至9月期間進行了一項有關脊椎健康的問卷調查,共收集 […]
【肝炎肝癌】為己又為人 丙肝可斷尾 盡早醫免傷「肝」|劉煥楠醫生
丙型肝炎是一種由病毒感染引致的肝炎,不似乙型肝炎般普遍,但破壞力卻同樣厲害,可以誘發肝硬化及肝癌等嚴重併發症。 […]
【世界肺癌大會】癌症資訊網慈善基金首次參與世界肺癌大會 分享低劑量肺部電腦掃描肺癌篩查計劃成果
癌症資訊網慈善基金首次參與世界肺癌大會(WCLC) 分享低劑量肺部電腦掃描肺癌篩查計劃成果 瀏覽 “ […]
【精準醫療】行動基因香港與癌症資訊網合作 推廣癌症患者的精準醫療
行動基因香港與癌症資訊網合作 推廣癌症患者的精準醫療 Sep 11th, 2024 香港–行動基因 […]
香港大學李嘉誠醫學院獲捐贈亞洲首部國際級創新儀器 突破性組織碎化技術 高效益、無創、無痛肝癌最新療法
香港大學李嘉誠醫學院(港大醫學院)獲李嘉誠基金會(基金會)捐贈亞洲首部突破性醫療儀器Histotripsy系統 […]